BioTech 365

MAY 20, 2021

–(BUSINESS WIRE)–#BioCapital–Today, the Maryland Tech Council (MTC), Maryland’s largest technology and life sciences trade association, announced the winners for its annual … Continue reading →

Life Science 52

Life Science 52

BioTech 365

JANUARY 14, 2021

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program Founding investor Forbion joined by co-lead investors, Morningside Ventures and Ascendant BioCapital, … Continue reading →

Development 52

Development 52

BioTech 365

SEPTEMBER 16, 2020

— Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital — — Core technology from Stanford founders Matt Porteus and Maria Grazia Roncarolo — — Josh Lehrer joins as CEO — SOUTH SAN FRANCISCO, Calif.–(BUSINESS

Gene Editing 40

Gene Editing Gene 40

Drug Discovery World

SEPTEMBER 25, 2023

million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. AbolerIS Pharma has raised €27.3 Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness in additional autoimmune diseases.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

BioTech 365

SEPTEMBER 17, 2020

Series A led by Canaan Partners, Samsara BioCapital and The Column Group Foundational research into cytokine structural biology and immune function licensed from Stanford University Nils Lonberg joins founding investors on board of directors MENLO PARK, Calif.–(BUSINESS –(BUSINESS WIRE)–Synthekine Inc.,

Engineer 40

Engineer Licensing Licensing Research 40

BioTech 365

SEPTEMBER 25, 2020

— Led by Samsara BioCapital — Advancing Phase 3 ALERT Study HORSHAM, Pa.–(BUSINESS –(BUSINESS WIRE)–Palladio Biosciences, Inc.

Medicine 40

Medicine Development 40

Drug Discovery World

SEPTEMBER 29, 2023

million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. The top stories: €27.3M to advance monoclonal antibody for autoimmune diseases AbolerIS Pharma has raised €27.3

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

pharmaphorum

MARCH 10, 2022

The latest funding round was led by Eir Ventures, BioMedPartners and Vesalius Biocapital, alongside existing investors Inkef Capital, BioGeneration Ventures and Oxford Science Enterprises as well as founders and management. The post Scenic Bio raises $31m for genetic modifier platform appeared first on.

Genetics 98

Genetics Gene Sequencing Gene Clinical Trials 98

pharmaphorum

JANUARY 13, 2021

Other new investors joining the round included Vivo Capital, Kurma Partners, Avoro Capital, RA Capital, Samsara Biocapital, Idinvest Partners (Subsidiary of Eurazeo), PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital.

Vaccination 95

Vaccination Vaccine Development In-Vivo 95

pharmaphorum

NOVEMBER 12, 2020

The round was led by Vesalius Biocapital III, with participation from Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors Forbion and BioGeneration Ventures. Founded in 2016 as a spin-out from Wuerzburg University, CatalYm’s lead molecule CTL-002 is designed to neutralise the tumour-produced protein GDF-15.

Protein 105

Protein Trials Drugs Research 105

The Pharma Data

APRIL 9, 2021

The company was seeded by Mission BioCapital, and joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures, and AbbVie Ventures.

In-Vivo 52

In-Vivo Research Genetics Development 52

Drug Discovery World

NOVEMBER 2, 2022

The financing was led by Medicxi with participation from new investors, OrbiMed and Monograph Capital and existing Series A investors, Oxford Science Enterprises, Samsara BioCapital, SR One and Advent Life Sciences. .

Life Science 52

Life Science Clinical Trials Clinical Trials Marketing 52

The Pharma Data

DECEMBER 21, 2020

Acticor Biotech is backed by a syndicate of European and International investors: Karista, Go Capital, Newton Biocapital, CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital & Armesa Foundation. For more information, go to: [link]. View source version on businesswire.com: [link].

In-Vivo 52

In-Vivo Production Antibody Development 52

The Pharma Data

JANUARY 12, 2021

The financing round was led by HBM Healthcare Investments, and other new investors joining the round included Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners 1 , PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital, with the participation of existing investors Novo Seeds , Lundbeckfonden (..)

In-Vivo 52

In-Vivo Antibody Vaccination Vaccine 52

Pharmaceutical Technology

SEPTEMBER 9, 2022

The existing shareholders who have participated in the financing round include Cowen Healthcare Investments, Pfizer Ventures, Samsara BioCapital, BVF Partners, ARCH Venture Partners, Biogen, Bristol Myers Squibb, Invus, Section 32, Alexandria Venture Investments and GT Healthcare. Biotechnology company Autobahn Therapeutics has raised $32.7m

Hormones 147

Hormones Clinical Development Development Drugs 147

The Pharma Data

NOVEMBER 8, 2020

The financing was led by OrbiMed, with new investments from BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital and Surveyor Capital (a Citadel company).

Gene Therapy 40

Gene Therapy Gene Gene Expression Genome 40

The Pharma Data

NOVEMBER 18, 2021

MBC BioLabs has hookups with leading pharmaceutical and life- wisdom companies as well as a erected-in adventure capital establishment, Mission BioCapital. Each point has a complete molecular biology core installation that allows companies to do trials on day one. Since opening in 2013, MBC BioLabs has helped launch and grow 230 companies.

Development 52

Development Scientist Medicine Clinical Development 52

The Pharma Data

SEPTEMBER 15, 2020

We have partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one.

Life Science 52

Life Science Protein Antibody Scientist 52